Key Takeaways
|
A few years ago, a once-a-week injection for weight loss would have sounded unlikely. Today, semaglutide and tirzepatide are among the most talked-about medicines in India. Many people ask us whether they work, whether they are safe and whether they replace diet and exercise.
This guide explains what weight loss injections are, how they work, who they may suit, what weight loss to expect and what lifestyle care adds. It is for information only. It is not a recommendation to start or stop any medicine.
Thinking about your weight, blood sugar or a weight loss injection?
What Are Weight Loss Injections?
A weight loss injection is a prescription medicine, given under the skin once a week, that lowers appetite and helps people with obesity or overweight lose weight. The medicines were first developed for type 2 diabetes. Doctors noticed that people lost weight while taking them, and later studies confirmed that effect.
Two active ingredients account for most of the interest in India:
| Semaglutide. It copies only one gut hormone called GLP-1. Tirzepatide. It copies two gut hormones, GIP and GLP-1. |
What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It is a hormone that your intestine releases after you eat. It does several useful things at once (Drucker, 2018)
- It tells the brain that you are full, so appetite and food cravings go down.
- It slows how fast the stomach empties, so you feel full for longer.
- It helps the pancreas release insulin when blood sugar is high and lowers a hormone that raises sugar.
Natural GLP-1 breaks down in minutes. GLP-1 medicines are made to last, so one injection can work for a week. Tirzepatide adds the action of a second hormone, GIP, which may add to the effect on appetite and blood sugar (Coskun et al., 2018).
“GLP-1 medicines work on the body’s natural systems that regulate hunger, fullness and blood sugar. In my clinical experience, understanding these effects helps patients see why weight management involves more than eating less. The right treatment depends on your weight, metabolic health, medical history and response to therapy. These medicines should always be used under medical supervision, alongside sustainable dietary and lifestyle changes.”
– Dr. Bipin Gond, Zonal Medical Head, Madhavbaug
Ozempic, Wegovy, Mounjaro and Rybelsus
People often search for Ozempic for weight loss or Mounjaro for weight loss, but the brand names can be confusing. The following table sets them out.
| Brand | Medicine | How it is taken | Main approved use in India |
| Ozempic | Semaglutide | Weekly injection | Type 2 diabetes |
| Wegovy | Semaglutide (higher dose) | Weekly injection | Weight management |
| Mounjaro | Tirzepatide | Weekly injection | Type 2 diabetes and weight management |
| Rybelsus | Semaglutide | Daily tablet | Type 2 diabetes |
Since March 2026, after the main Indian patent on semaglutide expired, several Indian companies have launched their own semaglutide injections under other brand names (Pearce IP, 2026). The medicine inside is the same, but doses, pens and approved uses differ by product, so always check the exact product and dose with your doctor.
Mounjaro in India
Tirzepatide was launched in India as Mounjaro in March 2025, and the pen form (KwikPen) was approved in June 2025. It is approved along with diet and exercise for adults with type 2 diabetes, for adults with a BMI of 30 or more, and for adults with a BMI of 27 or more who also have a weight-related condition such as high blood pressure or high cholesterol (Business Standard, 2025). Interest in Mounjaro India has grown quickly and is also compared with Ozempic. very often.
How Much Weight Can You Lose Using Weight Loss Injections?
The numbers below come from large clinical trials. They describe the average result of a group, in people who also received diet and activity advice. Your own result may be higher or lower.
| Trial | Medicine and dose | Average weight loss | Comparison group |
| STEP 1, 68 weeks | Semaglutide 2.4 mg weekly | About 15 per cent of body weight | About 2.4 per cent with placebo (Wilding et al., 2021) |
| SURMOUNT-1, 72 weeks | Tirzepatide 5, 10 or 15 mg weekly | About 15 to 21 per cent, depending on dose | About 3 per cent with placebo (Jastreboff et al., 2022) |
| SURMOUNT-5, 72 weeks | Tirzepatide vs semaglutide, highest tolerated doses | About 20 per cent vs about 14 per cent | Head-to-head comparison (Aronne et al., 2025) |
These trials enrolled adults with obesity but without diabetes. People with type 2 diabetes usually lose less weight on the same medicines. Most of the loss happens in the first year, and then it levels off.
| Clinical Insight “In our clinical experience, weight loss varies from person to person. From an Ayurvedic perspective, understanding your Agni (digestive fire), dietary habits and daily routine helps guide a personalised approach to weight management.” Dr. Pravin Jayram Ghadigaonkar, BAMS, MD, PhD (Scholar) – Preventive Cardiology 20+ Years of Clinical Experience, Head Medical Operations & Patient Improvement, Madhavbaug |
Who Do Weight Loss Injections Suit?
These medicines are meant for adults whose weight or blood sugar is affecting their health. A doctor looks at your whole health picture before deciding. Indian doctors also keep in mind that South Asians can carry health risks at a lower BMI and a smaller waist than Western guidelines assume (Misra et al., 2009).
| Who it may suit | Usually not advised or needs extra care | |
| Weight | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, high cholesterol or sleep apnoea | Normal weight, or wanting to lose a few kilos for appearance |
| Blood sugar | Adults with type 2 diabetes, where a doctor judges the medicine suitable | Type 1 diabetes, as these medicines do not replace insulin |
| Medical history | No history that raises the risks listed in the next column | Personal or family history of medullary thyroid cancer or MEN 2; past pancreatitis; gallbladder disease; severe stomach or bowel problems; diabetic eye disease; kidney disease; eating disorder |
| Life stage | Adults who are not pregnant | Pregnancy, planning pregnancy or breastfeeding |
| Other medicines | Taken with a plan for dose changes | Insulin or sulfonylurea tablets, which can cause low blood sugar when combined |
This table is a guide only. Your doctor will decide based on your tests and history. If you have heart disease, there is also some evidence of benefit. In the SELECT trial, semaglutide lowered the chance of heart attack, stroke and cardiovascular death in adults with heart disease and overweight, but without diabetes (Lincoff et al., 2023).
How Doctors Decide
A good start is a proper check-up, not a prescription on the first day. The path below shows how most careful treatment plans run. It is a general picture, and your doctor may do things differently.
The check-up comes first. A medicine plan starts only if an injection suits you, and both paths lead to regular review.
What Lifestyle Care Adds to a Weight Loss Injection
The injections were tested alongside diet and activity advice. They are not a substitute for it. Lifestyle care matters in four ways.
It protects muscle.
Some of the weight lost on these medicines is lean mass, not only fat. In some studies, about a quarter or more of the weight lost was lean mass (Neeland et al., 2024). Protein-rich meals and strength exercise help protect muscle.
It eases side effects.
Smaller meals, enough fluids and fibre can reduce nausea and constipation.
It helps keep weight off.
After the medicine is stopped, hunger returns, and so does weight unless new habits are in place.
It treats what the injection does not.
Sleep, stress, meal timing and activity affect blood sugar, blood pressure and cholesterol.
| Area | Why it matters on an injection | What can help |
| Protein | Protects muscle when appetite is low | Dal, curd, paneer, eggs, fish, sprouts at each meal. |
| Strength and walking | Keeps muscle and bone strong | Walking daily and simple resistance exercise as your doctor advises |
| Meal size and timing | Large or oily meals can cause nausea and bloating | Small, slow meals and an early, light dinner. |
| Fluids and fibre | Reduces dehydration and constipation | Water, buttermilk, vegetables, fruit, whole grains |
| Sleep and stress | Poor sleep and stress raise hunger and sugar | Regular sleep time, stress relief. |
| Monitoring | Shows whether the plan works | Weight, waist, HbA1c, blood pressure and lipids at regular visits |
What Happens When You Stop the Injection?
Obesity is a long-term condition, and these medicines work only while they are used. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year (Wilding et al., 2022). In SURMOUNT-4, people who switched from tirzepatide to placebo regained weight, while those who continued lost more (Aronne et al., 2024).
This does not mean you must stay on an injection for life. It means you should plan ahead. Talk to your doctor early about how long to use the medicine, how to taper or stop and which habits to build in the meantime.
Side Effects of Weight Loss Injections
The most common side effects are nausea, vomiting, diarrhoea, constipation, stomach pain and reduced appetite. They are usually mild to moderate and are worst when the dose is increased. Less common but serious problems include pancreatitis, gallstones, dehydration with kidney injury and severe allergic reactions (Sodhi et al., 2023).
| When Should You Talk to a Doctor? See your doctor if your weight or waist is rising, your blood sugar or HbA1c is above target, you have high blood pressure or cholesterol, or you are thinking of a weight loss injection. Seek urgent care if, while on an injection, you have severe or lasting stomach pain, repeated vomiting, signs of dehydration, a yellow tinge to the skin, sudden vision changes or swelling of the face or throat. |
Lifestyle and Ayurvedic Care For Weight Loss at Madhavbaug
Obesity care at Madhavbaug starts with a madhavbaug doctors looking at weight, waist, blood sugar, blood pressure and cholesterol together and planning food, activity, sleep and Ayurvedic care around each person. If you already take prescription medicines, including diabetes medicines or injections, please tell your Madhavbaug doctor. Please do not stop or change a prescribed medicine on your own.
Sustainable weight loss takes time, consistency and the right medical guidance. With a personalised plan that combines healthy eating, regular physical activity, better sleep and doctor-supervised Ayurvedic care, you can work towards a healthier weight while improving your overall metabolic health. Start with a health assessment at Madhavbaug to understand your needs and take the next step towards long-term weight management.
For appointments or general enquiries, reach out to your nearest Madhavbaug clinic.
To get a clearer picture of your own diabetes, use the Diabetes Assessment Tool and share the result with your doctor at your next consultation.
Frequently Asked Questions
What is a weight loss injection?
It is a prescription medicine, taken once a week under the skin, that lowers appetite and helps adults with obesity or overweight to lose weight. The main ones contain semaglutide or tirzepatide.
What is GLP-1?
GLP-1 is a hormone released by the gut after meals. It signals fullness, slows stomach emptying and helps insulin work when blood sugar is high. GLP-1 medicines copy this hormone.
Can I use Ozempic for weight loss?
Ozempic is approved for type 2 diabetes and contains semaglutide. The same medicine at a higher dose is sold as Wegovy for weight management. Only a doctor can decide which product and dose suits you.
Is Mounjaro available in India?
Yes. Mounjaro (tirzepatide) was launched in India in 2025 for type 2 diabetes and for weight management in adults who meet the approved criteria. It is a prescription medicine.
How much weight can I lose with Mounjaro or semaglutide?
In trials, adults with obesity lost about 15 per cent of body weight on semaglutide 2.4 mg and about 15 to 21 per cent on tirzepatide over 68 to 72 weeks. People with diabetes usually lose less, and individual results vary.
Do I regain weight after stopping a weight loss injection?
Many people do. In one trial extension, about two-thirds of the lost weight returned within a year of stopping. Lasting habits and a follow-up plan help.
Can lifestyle care replace weight loss injections?
For many people with milder weight problems, structured food, activity, sleep and stress care is the first step. Injections are usually considered when weight or health risks remain high. Your doctor can advise on which path fits you.
References
Aronne, L.J., Horn, D.B., le Roux, C.W., et al. (2025) ‘Tirzepatide as compared with semaglutide for the treatment of obesity’, New England Journal of Medicine, 393(1), pp. 26-36.
Aronne, L.J., Sattar, N., Horn, D.B., et al. (2024) ‘Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial’, JAMA, 331(1), pp. 38-48.
Business Standard (2025) India approves Eli Lilly’s Mounjaro pen for diabetes, weight control. 26 June.
Coskun, T., Sloop, K.W., Loghin, C., et al. (2018) ‘LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept’, Molecular Metabolism, 18, pp. 3-14.
Drucker, D.J. (2018) ‘Mechanisms of action and therapeutic application of glucagon-like peptide-1’, Cell Metabolism, 27(4), pp. 740-756.
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022) ‘Tirzepatide once weekly for the treatment of obesity’, New England Journal of Medicine, 387(3), pp. 205-216.
Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., et al. (2023) ‘Semaglutide and cardiovascular outcomes in obesity without diabetes’, New England Journal of Medicine, 389(24), pp. 2221-2232.
Misra, A., Chowbey, P., Makkar, B.M., et al. (2009) ‘Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management’, Journal of the Association of Physicians of India, 57, pp. 163-170.
Neeland, I.J., Linge, J., Birkenfeld, A.L. (2024) ‘Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies’, Diabetes, Obesity and Metabolism, 26(Suppl 4), pp. 16-27.
Pearce IP (2026) Generic semaglutide launches in India, including by Dr Reddy’s, Zydus, Alkem, Sun Pharma & Glenmark. 21 March.
Sodhi, M., Rezaeianzadeh, R., Kezouh, A. and Etminan, M. (2023) ‘Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss’, JAMA, 330(18), pp. 1795-1797.
Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021) ‘Once-weekly semaglutide in adults with overweight or obesity’, New England Journal of Medicine, 384(11), pp. 989-1002.
Wilding, J.P.H., Batterham, R.L., Davies, M., et al. (2022) ‘Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension’, Diabetes, Obesity and Metabolism, 24(8), pp. 1553-1564. doi:10.1111/dom.14725.








